{
  "scenario_id": "quantum_algorithm_development_investment_2025",
  "context": "Mid-size pharmaceutical company investing in quantum algorithms for drug discovery optimization",
  "stakeholders": {
    "requester": "VP Research & Development",
    "approvers": [
      "CEO",
      "CFO",
      "Chief Scientific Officer"
    ],
    "influencers": [
      "Head of Computational Chemistry",
      "VP IT",
      "External Quantum Consultants"
    ]
  },
  "request": {
    "amount": "$15 million",
    "purpose": "Development of quantum algorithms for molecular simulation and drug candidate screening",
    "urgency": "medium",
    "justification": "Quantum advantage could accelerate drug discovery by 10x, reducing time-to-market for critical therapies"
  },
  "decision_process": [
    {
      "stage": "scientific_evaluation",
      "duration": "6 weeks",
      "activities": [
        "Quantum advantage validation for molecular simulations",
        "Current classical method limitations assessment",
        "Algorithm development feasibility study"
      ],
      "outcome": "Strong quantum advantage identified for specific molecular interaction calculations"
    },
    {
      "stage": "technical_assessment",
      "duration": "4 weeks",
      "activities": [
        "Hardware requirements analysis",
        "Integration with existing computational chemistry platforms",
        "Talent and partnership needs evaluation"
      ],
      "outcome": "Requires hybrid quantum-classical approach with specialized development team"
    },
    {
      "stage": "financial_modeling",
      "duration": "3 weeks",
      "activities": [
        "Development cost breakdown",
        "Timeline and milestone projections",
        "Expected ROI from accelerated drug discovery"
      ],
      "outcome": "Projected 8x ROI over 7 years with successful algorithm development"
    },
    {
      "stage": "risk_mitigation",
      "duration": "2 weeks",
      "activities": [
        "Technology risk assessment",
        "Alternative classical optimization strategies",
        "Regulatory and IP considerations"
      ],
      "outcome": "Acceptable risk with fallback strategies and IP protection measures"
    }
  ],
  "business_impact": {
    "expected_benefits": [
      "10x faster drug candidate screening",
      "Reduced R&D costs by 30%",
      "Faster time-to-market for new therapies"
    ],
    "projected_revenue": "$500 million in additional revenue from accelerated drug pipeline",
    "risk_factors": [
      "Algorithm development complexity",
      "Hardware access limitations",
      "Integration with existing workflows",
      "Regulatory approval timelines"
    ]
  }
}
